<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639051</url>
  </required_header>
  <id_info>
    <org_study_id>D0543</org_study_id>
    <nct_id>NCT03639051</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of TLD in Patients With COPD</brief_title>
  <acronym>AIRFLOW-3</acronym>
  <official_title>A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment With the Nuvairaâ„¢ Lung Denervation System in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvaira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvaira, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung&#xD;
      Denervation System (Nuvaira System) in the treatment of COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate the superiority of treatment with the&#xD;
      Nuvaira Lung Denervation System (Active Treatment arm) compared to a sham procedure (Sham&#xD;
      Control arm) to decrease moderate or severe exacerbations in subjects with COPD on optimal&#xD;
      medical care.&#xD;
&#xD;
      The secondary objective is to compare long-term safety, and other efficacy assessments&#xD;
      between the Active Treatment arm and the Sham Control arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized with equal allocation (1:1) into two arms: TLD therapy plus optimal medical care (Active Treatment) and optimal medical care (Sham Control). Randomization of subjects will be stratified based on investigational site, participation in a pulmonary rehabilitation maintenance program and baseline use of an inhaled corticosteroid at the time of enrollment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Subject and assessor double-blinding will be maintained through 1 year post-procedure.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Moderate or severe COPD exacerbations</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>A COPD exacerbation will be defined as a complex of respiratory events/symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnea or chest tightness with at least one symptom lasting three days requiring treatment with antibiotics and/or systemic steroids (moderate exacerbation) and/or hospital admission (severe exacerbation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first severe COPD exacerbation</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the survival distributions for events based on log-rank tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first severe COPD exacerbation (Subgroup)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Defined as a comparison between study arms of the survival distributions for events based on log-rank tests, only for the subgroup of subjects who had a severe COPD exacerbation in the year prior to randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in St. George's Respiratory Questionnaire COPD Version (SGRQ-C) Total score</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in FVC based on a linear model for change in SGRQ-C, adjusted for baseline SGRQ-C.&#xD;
The SGRQ-C is a disease-specific HRQL questionnaire with a total and three component scores for: symptoms, activity and impacts; each score ranges from 0 (no impairment) to 100 (worst possible). A difference in four units in the SGRQ-C score is considered the minimum clinically important difference (MCID).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FVC</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as a comparision between study arms of the mean change in FVC based on a linear model for change in FVC, adjusted for baseline FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in FEV1 based on a linear model for change in FEV1, adjusted for baseline FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition Dyspnea Index (TDI)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Defined as a comparison between study arms of the TDI based on a linear model for change in TDI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RV</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in RV based on a linear model for change in RV, adjusted for baseline RV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first respiratory-related hospitalization</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the survival distributions for events based on log-rank tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form Health Survey (SF-36) total score</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the mean change in SF-36 total score based on a linear model for change in SF-36 total score, adjusted for baseline SF-36 total score.&#xD;
SF-36 is composed of eight multi-item scales (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, Mental Health), with scores for each of these scales (or dimensions) ranging from 0 to 100. Higher scores indicate higher HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAT responders</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as a comparison between study arms of the proportion of subjects with a greater than or equal to 2 point decrease in CAT.&#xD;
The CAT is a disease-specific HRQL with eight questions; each score ranges from 0 (no impairment) to 5 (worst possible). The CAT has a scoring range of 0-40. Higher scores denote a more severe impact of COPD on a patient's life. A difference in 2 units in the CAT score over 2 to 3 months suggests a clinically significant difference or change in health status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Randomization to 6, 12 Months</time_frame>
    <description>Change in St. George's Respiratory Questionnaire (SGRQ-C), COPD Assessment Test (CAT) and Short Health Survey (SF-36) scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event rates</measure>
    <time_frame>Randomization to 12 Months, 3 to 12 Months</time_frame>
    <description>Defined as the total number of events per total number of treatment years including moderate or severe COPD exacerbations, severe COPD exacerbations, respiratory-related hospitalizations, and lower respiratory-related adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to first event</measure>
    <time_frame>3 to 12 Months</time_frame>
    <description>Defined as comparison between study arms of the survival distributions for events based on log-rank tests including moderate or severe COPD exacerbations, severe exacerbations and respiratory-related hospitalizations</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in lung function</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Changes in Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC) and Body plethysmography measures (IC, TLC, RV)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in dyspnea</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Changes in dyspnea including Modified Medical Research Council (mMRC) Dyspnea Scale scores and Baseline and Transition Dyspnea Indexes (BDI/TDI) scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Healthcare utilization</measure>
    <time_frame>Randomization to 12 Months</time_frame>
    <description>Defined as respiratory-related unscheduled clinic visits, ER visits and hospitalizations</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Targeted Lung Denervation (TLD)</intervention_name>
    <description>Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvairaâ„¢ Lung Denervation System.</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <other_name>TLD, TLD Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Care</intervention_name>
    <description>Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).</description>
    <arm_group_label>Active Treatment</arm_group_label>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject â‰¥40 years of age at the time of consent;&#xD;
&#xD;
          -  Women of child bearing potential must not be pregnant, evidenced by a negative&#xD;
             pregnancy test (blood or urine) pre-treatment, or lactating and agree not to become&#xD;
             pregnant for the duration of the study;&#xD;
&#xD;
          -  Smoking history of at least 10 pack years;&#xD;
&#xD;
          -  Not smoking or using any other inhaled substance (e.g., cigarettes, vaping, cannabis,&#xD;
             pipes) for a minimum of 2 months prior to consent and agrees to not start for the&#xD;
             duration of the study;&#xD;
&#xD;
          -  Subject has received a flu vaccination within the 12 months prior to the procedure or&#xD;
             agrees to obtain vaccination once it becomes available and agrees to annual&#xD;
             vaccinations for the duration of the study;&#xD;
&#xD;
          -  Resting SpO2 â‰¥89% on room air at the time of screening;&#xD;
&#xD;
          -  CAT score â‰¥10 at the time of screening;&#xD;
&#xD;
          -  Diagnosis of COPD with 25%â‰¤ FEV1 â‰¤80% of predicted, PaCO2 Ë‚ 50 (if FEV1 Ë‚30%) and&#xD;
             FEV1/FVC &lt;70% (post-bronchodilator);&#xD;
&#xD;
          -  Documented history of â‰¥ 2 moderate COPD exacerbations or â‰¥ 1 severe COPD exacerbation&#xD;
             leading to hospitalization in the 12 months prior to consent with at least one&#xD;
             exacerbation occurring while the subject was on optimal medical care (taking LAMA and&#xD;
             a LABA, or scheduled SABA or SAMA instead of either a LAMA or LABA, not both, as&#xD;
             regular respiratory maintenance medication);&#xD;
&#xD;
          -  Subject is on optimal medical care at the time of consent;&#xD;
&#xD;
          -  If subject has participated in a formal pulmonary rehabilitation program recently,&#xD;
             program completion must have occurred â‰¥3 months prior to consent; if in a maintenance&#xD;
             program, subject agrees to continue their current program through their 12-month&#xD;
             follow-up visit;&#xD;
&#xD;
          -  Subject is a candidate for bronchoscopy in the opinion of the physician or per&#xD;
             hospital guidelines and is able to discontinue blood thinning medication&#xD;
             peri-procedurally;&#xD;
&#xD;
          -  The subject is able and agrees to complete all protocol required baseline and&#xD;
             follow-up tests and assessments including taking certain medications (e.g.,&#xD;
             azithromycin, prednisolone/prednisone);&#xD;
&#xD;
          -  Subject has provided written informed consent using a form that has been reviewed and&#xD;
             approved by the Institutional Review Board (IRB)/Ethics Committee (EC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index &lt;18 or &gt;35;&#xD;
&#xD;
          -  Subject has an implantable electronic device and has not received appropriate medical&#xD;
             clearance;&#xD;
&#xD;
          -  Uncontrolled diabetes in the opinion of the investigator;&#xD;
&#xD;
          -  Malignancy treated with radiation or chemotherapy within 1 year of consent;&#xD;
&#xD;
          -  Asthma as defined by the current Global Initiative for Asthma (GINA) guidelines;&#xD;
&#xD;
          -  Subject diagnosed with a dominant non-COPD lung disease or condition affecting the&#xD;
             lungs, which is the main driver of the subjects clinical symptoms (e.g., cystic&#xD;
             fibrosis, paradoxical vocal cord motion, eosinophilic granulomatosis with polyangiitis&#xD;
             (EGPA), allergic bronchopulmonary aspergillosis, interstitial lung disease or active&#xD;
             tuberculosis) or has a documented medical history of pneumothorax within 1 year of&#xD;
             consent;&#xD;
&#xD;
          -  Clinically relevant bronchiectasis, defined as severe single lobe or multilobar&#xD;
             broncial wall thickening associated with airway dilation on CT scan leading to cough&#xD;
             and tenacious sputum on most days;&#xD;
&#xD;
          -  Pre-existing diagnosis of pulmonary hypertension, clinical evidence of pulmonary&#xD;
             hypertension (e.g., cardiovascular function impairment including peripheral edema) and&#xD;
             mPAP â‰¥25 mmHg at rest by right heart catheterization (or estimated right ventricular&#xD;
             systolic pressure &gt;50 mmHg by echocardiogram if no previous right heart&#xD;
             catheterization);&#xD;
&#xD;
          -  Myocardial infarction within last 6 months, EKG with evidence of life threatening&#xD;
             arrhythmias or acute ischemia, pre-existing documented evidence of an LVEF &lt;40%, stage&#xD;
             C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other past&#xD;
             or present cardiac findings that make the subject an unacceptable candidate for a&#xD;
             bronchoscopic procedure utilizing general anesthesia;&#xD;
&#xD;
          -  Surgical procedure(s) on the stomach, esophagus or pancreas performed â‰¤2 years of&#xD;
             consent or ongoing related symptoms within the past year;&#xD;
&#xD;
          -  Symptomatic gastric motility disorder(s) (e.g., gastroparesis) as evidenced by a GCSI&#xD;
             score â‰¥18.0, severe uncontrolled GERD (e.g., refractory heartburn, endoscopic&#xD;
             esophagitis) or severe dysphagia (e.g., esophageal stricture, achalasia, esophageal&#xD;
             spasm);&#xD;
&#xD;
          -  Any disease or condition that might interfere with completion of a procedure or this&#xD;
             study (e.g., structural esophageal disorder, life expectancy &lt;3 years);&#xD;
&#xD;
          -  Prior lung or chest procedure (e.g., lung transplant, LVRS, BLVR, lung implant, metal&#xD;
             stent, valves, median sternotomy, bullectomy, lobectomy, segmentectomy or other&#xD;
             interventional lung or chest procedure) performed â‰¤1 year of consent; NOTE: Any metal&#xD;
             in the chest must be â‰¥5 cm away from the anticipated treatment location(s). Subjects&#xD;
             with explanted lung valve(s) allowed if explant occurred â‰¥3 months prior to treatment.&#xD;
&#xD;
          -  Daily use of &gt;10 mg of prednisone or its equivalent at the time of consent;&#xD;
&#xD;
          -  Chronic use of &gt;40 mg MEDD opioid only medication per day;&#xD;
&#xD;
          -  Known contraindication or allergy to medications required for bronchoscopy or general&#xD;
             anesthesia (e.g., lidocaine, atropine, propofol, sevoflurane) that cannot be medically&#xD;
             controlled;&#xD;
&#xD;
          -  Baseline chest CT scan reveals bronchi anatomy cannot be fully treated with available&#xD;
             catheter sizes, presence of severe emphysema &gt;50%, lobar attenuation area or severe&#xD;
             bullous disease (&gt;1/3 hemithorax) (as determined by the CT core lab using a single&#xD;
             density mask threshold of -950 HU) or discovery of a mass that requires treatment;&#xD;
&#xD;
          -  Subject is currently enrolled in another interventional clinical trial that has not&#xD;
             completed follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Sciurba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Peterson</last_name>
    <phone>651-398-4341</phone>
    <email>kpeterson@nuvaira.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB) Lung Health Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Necole Harris</last_name>
      <email>Nharris@uabmc.edu</email>
    </contact>
    <contact_backup>
      <phone>205-934-5555</phone>
    </contact_backup>
    <investigator>
      <last_name>Surya Bhatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lane</last_name>
      <phone>480-323-1292</phone>
      <email>hlane@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Richard Sue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Ramirez</last_name>
      <phone>916-734-3845</phone>
      <email>karamirez@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Ken Yoneda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Letty Diaz</last_name>
      <phone>310-222-3801</phone>
      <email>ldiaz@lundquist.org</email>
    </contact>
    <investigator>
      <last_name>David Hsia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. Vincent's</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alycia Hayes</last_name>
      <phone>904-425-7942</phone>
      <email>alycia.obryan@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Jose Soto-Soto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Warnes</last_name>
      <phone>773-834-8874</phone>
      <email>cwarnes@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Kyle Hogarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suburban Lung Associates</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carri Dohe</last_name>
      <phone>847-230-3537</phone>
      <email>carri.dohe@amitahealth.org</email>
    </contact>
    <investigator>
      <last_name>Neeraj Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crissie DeSpirito, RN</last_name>
      <phone>502-852-0026</phone>
      <email>crissie.despirito@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Umair Gauhar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lahey Hospital &amp; Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Pelletier</last_name>
      <phone>781-744-3706</phone>
      <email>joyce.e.pelletier@lahey.org</email>
    </contact>
    <investigator>
      <last_name>Carla Lamb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Bautistia</last_name>
      <phone>734-764-8146</phone>
      <email>gevalen@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Meilan Han, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Medical Group</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Cumbo-Nacheli, MD</last_name>
      <phone>616-267-8244</phone>
      <email>Gustavo.cumbo-nacheli@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Gustavo Cumbo-Nacheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Harrison</last_name>
      <phone>314-273-0837</phone>
      <email>emily.harrison@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Coles</last_name>
      <phone>919-668-3812</phone>
      <email>kathleen.coles@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Shier</last_name>
      <phone>919-684-9139</phone>
      <email>jessica.shier@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kamran Mahmood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Health of the Carolinas</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Williams, PhD, MPH</last_name>
      <phone>910-715-1922</phone>
      <email>jcwilliams@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Pritchett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamaal Saleh</last_name>
      <phone>614-366-2258</phone>
      <email>jamaal.saleh@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Ghattas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Criner</last_name>
      <phone>215-707-1559</phone>
      <email>helga.criner@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Zaldonis</last_name>
      <email>zaldonisdb2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Sciurba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Millan</last_name>
      <phone>843-792-0260</phone>
      <email>millanr@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Charlie Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Davids HealthCare</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Saini</last_name>
      <phone>512-544-8070</phone>
      <email>krishna.saini@stdavids.com</email>
    </contact>
    <investigator>
      <last_name>Dominic Dekeratry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Busch</last_name>
      <phone>713-441-3912</phone>
      <email>bbusch@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Kopas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nord - Klinik Floridsdorf</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Duller</last_name>
      <email>marina.duller@extern.wienkav.at</email>
    </contact>
    <investigator>
      <last_name>Arschang Valipour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Cedex 9</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Jondot</last_name>
      <email>MJondot@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Bruno Degano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Guibert, MD</last_name>
      <email>guibert.n@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Solen Nicol</last_name>
      <email>solen.nicol@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Christophe Gut-Gobert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnaud de Villeneuve Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Vachier</last_name>
      <email>isabelle.vachier@medbiomed.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Arnaud Bourdin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorene Philibert</last_name>
      <email>philibert.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Charles-Hugo Marquette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat-Claude Bernard Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kahina Bala</last_name>
      <email>kahina.bala@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Armelle Marceau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaux Bonnaire</last_name>
      <email>margaux.bonnaire@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Gaetan Deslee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Stauder</last_name>
      <email>julien.stauder@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Prof. Romain Kessler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thorax Klinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Rump</last_name>
      <email>brigitte.rump@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Felix Herth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieta Wijsman</last_name>
      <email>p.c.wijsman@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>Peter Bonta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorine Hartman</last_name>
      <email>j.hartman@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Prof. Dirk-Jan Slebos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Harefield Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Conway, MD</last_name>
      <email>F.Conway@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Prof. Pallav Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Immediately following publication, ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers whose proposed use of the data has been approved by a review committee identified for this purpose will have access to the data required to achieve aims in the approved proposal. Proposals should be directed to pjohnson@nuvaira.com. (Link to be provided).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

